22.33
0.60 (2.76%)
| Previous Close | 21.73 |
| Open | 21.84 |
| Volume | 2,084,930 |
| Avg. Volume (3M) | 3,073,256 |
| Market Cap | 5,327,134,208 |
| Price / Earnings (TTM) | 26.90 |
| Price / Earnings (Forward) | 28.99 |
| Price / Sales | 12.74 |
| Price / Book | 15.26 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Profit Margin | 46.35% |
| Operating Margin (TTM) | 32.60% |
| Diluted EPS (TTM) | 0.830 |
| Quarterly Revenue Growth (YOY) | 59.10% |
| Quarterly Earnings Growth (YOY) | 1,300.00% |
| Total Debt/Equity (MRQ) | 23.53% |
| Current Ratio (MRQ) | 5.97 |
| Operating Cash Flow (TTM) | 118.67 M |
| Levered Free Cash Flow (TTM) | 75.16 M |
| Return on Assets (TTM) | 21.24% |
| Return on Equity (TTM) | 81.64% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ADMA Biologics Inc | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.59% |
| % Held by Institutions | 88.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Perpetual Ltd | 31 Mar 2025 | 3,551,813 |
| Oberweis Asset Management Inc/ | 31 Dec 2024 | 3,342,560 |
| 52 Weeks Range | ||
| Median | 25.00 (11.96%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 04 Mar 2025 | 25.00 (11.96%) | Buy | 17.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Apr 2025 | Announcement | ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 |
| 28 Apr 2025 | Announcement | ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process |
| 07 Apr 2025 | Announcement | ADMA Biologics Statement on Tariffs |
| 03 Mar 2025 | Announcement | ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
| 28 Feb 2025 | Announcement | ADMA Biologics to Participate in the Raymond James Institutional Investor Conference |
| 25 Feb 2025 | Announcement | ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |